adalimumab tapering at 6 months' remission and 2 cases initiated adalimumab tapering at 9-12 months' remission. No patients had recurrent uveitis at 12 months' remission or longer in both groups. Adalimumab plus MTX were well tolerated in all patients. Conclusions: For maintaining remission of SpA-related uveitis, adalimumab tapering can be effective when combined with MTX. Initiation of the tapering after 12 months' remission largely lower the rate of recurrence. Methods: In this 16-week (wk), Phase 2, double-blind, dose-ranging study (NCT01786668), 2 207 adult pts meeting modified New York AS criteria were randomised 1:1:1:1 to PBO or tofacitinib 2, 5 or 10 mg twice daily (BID) for 12 wks. Clinical endpoints included in this post-hoc analysis were: Assessment of SpondyloArthritis International Society 20% improvement (ASAS20) and ASAS 40% improvement (ASAS40) response rates, AS disease activity score major improvement (ASDAS MI; change ≥2.0 from baseline), ASDAS inactive disease (ASDAS ID; <1.3), Bath AS disease activity index (BASDAI), Bath AS functional index (BASFI) and back pain. Pts (%) achieving MIC in SIJ, spine and both SIJ and spine, in tofacitinib and PBO groups, were summarised based on observed data, and pooled tofacitinib (5 and 10 mg BID) vs PBO data were compared using Fisher's exact test. Concordance between achieving MIC and Wk 12 clinical responses was assessed. Wk 12 clinical responses were compared between pts achieving/not achieving MIC. Results: MRI data for 164 pts were evaluated. Baseline demographics were generally balanced between treatment groups and typical of AS populations. Approximately 3 times more pts achieved MIC in SIJ or spine in the pooled tofacitinib group vs PBO (SIJ: 34.1% vs 11.8%, p<0.05; spine: 38.6% vs 11.8%, p<0.01). Achieving MIC in SIJ and spine correlated with clinical response. In pts on tofacitinib, ASAS20, ASAS40 and ASDAS MI responses were more likely in pts achieving MIC in SIJ or spine (Table) Methods: Pts had recent onset non-radiographic (nr)-axSpA fulfilling ASAS criteria. Study group: pts receiving ETN 50 mg once weekly for 2 yrs in EMBARK (NCT01258738). Control group: pts in a longitudinal cohort study not receiving biologics for 2 yrs (DESIR, NCT01648907). Outcome measure: change in structural lesions of erosion, backfill, fat metaplasia, and ankylosis. MRI images were read by 3 experienced readers unaware of image chronology and pt group, using the SpondyloArthritis Research Consortium of Canada SIJ Structural Score (SSS). 1 For each group, differences were calculated between percentages of patients experiencing increases and decreases in structural lesion scores over 2
Background:
Tofacitinib is an oral Janus kinase inhibitor. The minimally important changes (MICs) for the SPondyloArthritis Research Consortium of Canada (SPARCC) MRI sacroiliac joint (SIJ) and spine scores based on agreement with global change scores by readers are ≥2.5 and ≥5, respectively. Objectives: To assess whether MIC in SIJ and spine can discriminate between tofacitinib and placebo (PBO) in patients (pts) with ankylosing spondylitis (AS) and if this is concordant with clinical responses. Methods: In this 16-week (wk), Phase 2, double-blind, dose-ranging study (NCT01786668), 2 207 adult pts meeting modified New York AS criteria were randomised 1:1:1:1 to PBO or tofacitinib 2, 5 or 10 mg twice daily (BID) for 12 wks. Clinical endpoints included in this post-hoc analysis were: Assessment of SpondyloArthritis International Society 20% improvement (ASAS20) and ASAS 40% improvement (ASAS40) response rates, AS disease activity score major improvement (ASDAS MI; change ≥2.0 from baseline), ASDAS inactive disease (ASDAS ID; <1.3), Bath AS disease activity index (BASDAI), Bath AS functional index (BASFI) and back pain. Pts (%) achieving MIC in SIJ, spine and both SIJ and spine, in tofacitinib and PBO groups, were summarised based on observed data, and pooled tofacitinib (5 and 10 mg BID) vs PBO data were compared using Fisher's exact test. Concordance between achieving MIC and Wk 12 clinical responses was assessed. Wk 12 clinical responses were compared between pts achieving/not achieving MIC. Results: MRI data for 164 pts were evaluated. Baseline demographics were generally balanced between treatment groups and typical of AS populations.
2
Tofacitinib 2, 5 and 10 mg BID improved mean (range) SPARCC scores vs PBO (SIJ: -2.2 [-22.0, 10.5], -3.5 [-34.5, 11.0], -3.6 [-29.0, 0.5] vs -0.7 [-9.5, 6 .5]; spine: -3.2 [-34.5, 20 .5], -5.5 [-36.5, 8.0], -6.7 [-32.5, 7.5] vs -0.8 [-8.0, 14.0] 
Methods:
Patients were randomized 1:1 to continued INX or switch to CT-P13. Serum drug levels were analyzed by automated in-house assay. The primary endpoint was disease worsening according to disease-specific composite measures and/or consensus between investigator/patient. Exploratory subgroup analyses examined disease worsening and safety in SpA. The primary endpoint was analysed by logistic regression, adjusted for diagnosis and disease duration. Results: Demographics, occurrence of disease worsening, change in disease measures and treatment-emergent adverse events (TEAE) were similar (Table) , as were serum drug levels for INX and CT-P13 ( Figure) .
Conclusions:
Explorative analyses in the NOR-SWITCH study showed similar efficacy, drug levels and safety in SpA patients switched to CT-P13 as those on continuous INX. The study was not powered to show non-inferiority within each diagnosis. References: [1] Jørgensen KK et al. Switching from originator infliximab to biosimilar CT-P13 compared to maintained treatment with originator infliximab (NOR-SWITCH): a 52-week randomised double-blind non-inferiority trial. The Lancet, in press. Disclosure of Interest: G. Goll Consultant for: AbbVie, Boehringer Ingelheim,
